KEGG   DRUG: Filgrastim
Entry
D03235                      Drug                                   
Name
Filgrastim (USP/INN);
Filgrastim (genetical recombination) (JP18);
Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN);
Tbo-filgrastim;
Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN);
Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN);
Filgrastim-sndz;
Filgrastim-aafi;
Neupogen (TN);
Nivestym (TN);
Grastofil (TN);
Zarxio (TN)
Product
GRANIX (Cephalon), NEUPOGEN (Amgen), NIVESTYM (Pfizer Laboratories Div Pfizer), RELEUKO (Amneal Pharmaceuticals LLC), ZARXIO (Sandoz)
Formula
C845H1339N223O243S9
Exact mass
18786.6761
Mol weight
18798.6065
Sequence
MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL LGHSLGIPWA
PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL GPTLDTLQLD VADFATTIWQ
QMEELGMAPA LQPTQGAMPA FASAFQRRAG GVLVASHLQS FLEVSYRVLR HLAQP
(Disulfide bridge: 37-43, 65-75)
  Type
Peptide
Class
Immunological agent
 DG01753  Colony stimulating factor
  DG01781  Granulocyte colony stimulating factor (G-CSF)
Remark
Therapeutic category: 3399
ATC code: L03AA02
Product: D03235<JP/US>
Efficacy
Antineutropenic, Hematopoietic stimulant, Antineoplastic (enhancer), Granulocyte colony stimulating factor (G-CSF)
  Disease
Neutropenia [DS:H00100]
Comment
recombinant granulocyte colony stimulating factor (G-CSF) [HSA:1440] [KO:K05423]
Target
CSF3R (GCSFR, CD114) [HSA:1441] [KO:K05061]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04151  PI3K-Akt signaling pathway
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
hsa05200  Pathways in cancer
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L03 IMMUNOSTIMULANTS
   L03A IMMUNOSTIMULANTS
    L03AA Colony stimulating factors
     L03AA02 Filgrastim
      D03235  Filgrastim (USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunostimulants
   Colony-stimulating Factors
    Filgrastim
     D03235  Filgrastim (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  33  Blood and body fluid agents
   339  Miscellaneous
    3399  Others
     D03235  Filgrastim (USP/INN); Filgrastim (genetical recombination) (JP18); Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN); Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN); Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG01753  Colony stimulating factor
   DG01781  Granulocyte colony stimulating factor (G-CSF)
    D03235  Filgrastim
Drug classes [BR:br08332]
 Immunological agent
  DG01753  Colony stimulating factor
   D03235  Filgrastim
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    CSF3R (GCSFR, CD114)
     D03235  Filgrastim (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D03235  Filgrastim (genetical recombination)
  D03235  Filgrastim (genetical recombination) injection
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03235
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03235
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03235
Other DBs
CAS: 121181-53-1
PubChem: 17397388
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system